Biotech Values

[caravon]

Long to median term sale predictions in high tech/science by professional analysts and amateur are very often nothing more speculations. People cannot make even accurate short term (up to 12 months) prediction.

Going back to HCV market. It is absolutely obvious that, in the next 3-5 years, a HCV treatment landscape will be very different from the present one but GILD having an excellent management team still will be a leader in HCV (either developing its one products and/or acquire the most promising ones. As for ABBV & Enta, they have to improve they act: ABBV needs a new CEO and ENTA must get off its ass during something productive rather than doing R@D for others).